Biogen Announces the Pricing Terms of Its Private Exchange Offer CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Biogen Inc...
Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE...
Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE...
Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis Intramuscular...
Biogen and Eisai Announce FDA’s 3-Month Extension of Review Period for the Biologics License Application for Aducanumab The new Prescription...
Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone The study aims to identify...
Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma®...
The European Commission Grants Marketing Authorization for PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for...
Biogen Files New Drug Application for Aducanumab in Japan If approved, aducanumab would become the first treatment to meaningfully change the...
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and...
Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab) INCHEON, South...
Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects...
Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease CAMBRIDGE, Mass. and TOKYO, Nov. 06, 2020 (GLOBE NEWSWIRE...
Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting In Phase 2 LILAC study...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.